Compare · ACXP vs LLY
ACXP vs LLY
Side-by-side comparison of Acurx Pharmaceuticals Inc. (ACXP) and Eli Lilly and Company (LLY): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ACXP and LLY operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- LLY is the larger of the two at $1.13T, about 184563.3x ACXP ($6.1M).
- Over the past year, ACXP is down 82.4% and LLY is up 48.0% - LLY leads by 130.4 points.
- LLY has been more active in the news (11 items in the past 4 weeks vs 2 for ACXP).
- LLY has more recent analyst coverage (25 ratings vs 1 for ACXP).
- Company
- Acurx Pharmaceuticals Inc.
- Eli Lilly and Company
- Price
- $1.41+0.00%
- $1196.14+0.89%
- Market cap
- $6.1M
- $1.13T
- 1M return
- -4.41%
- +7.05%
- 1Y return
- -82.37%
- +48.02%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2021
- News (4w)
- 2
- 11
- Recent ratings
- 1
- 25
Acurx Pharmaceuticals Inc.
Acurx Pharmaceuticals, LLC, a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. Its lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that has completed Phase II clinical trial to treat patients with clostridium difficile infections. The company is also developing ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumoniae. The company was founded in 2017 and is based in Staten Island, New York.
Eli Lilly and Company
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceuticals worldwide. It offers Baqsimi for severe hypoglycemia; Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500, and Lyumjev for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company also provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+ and HER2- metastatic breast cancer. In addition, it offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. Further, the company Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; Reyvow for migraine; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Additionally, it Bamlanivimab and etesevimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. Eli Lilly and Company has collaborations with Incyte Corporation; Pfizer Inc.; AC Immune SA; Centrexion Therapeutics Corporation; ImmuNext, Inc.; Avidity Biosciences, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; and MiNA Therapeutics Limited. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Latest ACXP
- Acurx Pharmaceuticals Announces Scientific Poster Presentation of Ibezapolstat's Microbiome Preservation Data in Multiply-recurrent C. difficile Infection
- Acurx Pharmaceuticals to Discuss Second Quarter 2026 Financial Results on August 14, 2026 Conference Call and Provide Business Update
- Acurx Pharmaceuticals Announces Presentation of Results from Leiden University Medical Center Public-Private Partnership for Its DNA pol IIIC Inhibitors at the Leiden Early Drug Discovery & Development (LED3) Scientific Conference
- SEC Form 424B3 filed by Acurx Pharmaceuticals Inc.
- SEC Form 424B3 filed by Acurx Pharmaceuticals Inc.
- Acurx Pharmaceuticals, Inc. Reports First Quarter 2026 results and Provides Business Update
- SEC Form EFFECT filed by Acurx Pharmaceuticals Inc.
- SEC Form EFFECT filed by Acurx Pharmaceuticals Inc.
- SEC Form 10-Q filed by Acurx Pharmaceuticals Inc.
- SEC Form S-1 filed by Acurx Pharmaceuticals Inc.
Latest LLY
- New insider Eli Lilly & Co claimed ownership of 1,054,828 shares (SEC Form 3)
- Lilly's triple agonist, retatrutide, successful in two additional Phase 3 obesity trials, delivering significant improvements in weight and A1C
- Lilly confirms date and conference call for second-quarter 2026 financial results announcement
- Director Sulzberger Gabrielle was granted 4 shares, increasing direct ownership by 0.14% to 3,000 units (SEC Form 4)
- Director Luciano Juan R was granted 14 shares, increasing direct ownership by 0.08% to 16,905 units (SEC Form 4)
- Director Fyrwald J Erik was granted 9 shares, increasing direct ownership by 0.01% to 75,410 units (SEC Form 4)
- Director Alvarez Ralph was granted 11 shares, increasing direct ownership by 0.02% to 55,734 units (SEC Form 4)
- Billions Flow Into Next-Generation Depression Treatments as Pharma Innovation Accelerates
- Big Pharma Just Paid Up to $3.8 Billion for Psychedelic Medicine, and the Rest of the Sector Is Being Repriced in Real Time
- Lilly to acquire AtaiBeckley to advance therapies for treatment-resistant depression and other mental health conditions